Xbiotech Stock Performance
| XBIT Stock | USD 2.39 0.05 2.14% |
The firm maintains a market beta of 2.14, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, XBiotech will likely underperform. At this point, XBiotech has a negative expected return of -0.0541%. Please make sure to check out XBiotech's potential upside, as well as the relationship between the rate of daily change and relative strength index , to decide if XBiotech performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days XBiotech has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable forward indicators, XBiotech is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors. ...more
Actual Historical Performance (%)
One Day Return 2.14 | Five Day Return (3.63) | Year To Date Return (42.69) | Ten Year Return (78.01) | All Time Return (89.72) |
Dividend Date 2021-07-23 | Ex Dividend Date 2021-07-15 |
1 | XBiotech Share Price Crosses Below 50-Day Moving Average - Should You Sell - MarketBeat | 10/10/2025 |
2 | How XBiotech Inc. stock trades after rate cuts - 2025 Performance Recap Advanced Swing Trade Entry Plans - newser.com | 10/24/2025 |
3 | Can XBiotech Inc. stock sustain free cash flow - Quarterly Investment Review Weekly Hot Stock Watchlists - newser.com | 10/27/2025 |
4 | Will XBiotech Inc. stock outperform foreign stocks - July 2025 Trends Weekly Market Pulse Alerts - newser.com | 10/31/2025 |
5 | Is XBiotech Inc. stock near bottom after decline - Weekly Trade Recap Verified Momentum Watchlists - newser.com | 11/03/2025 |
6 | November 2025s Promising Penny Stocks To Watch | 11/12/2025 |
7 | XBiotech Releases Earnings Results - MarketBeat | 11/13/2025 |
8 | Is XBiotech Inc. stock a top hedge fund pick - Quarterly Earnings Summary High Yield Equity Trading Tips - newser.com | 11/18/2025 |
9 | How XBiotech Inc. stock gains from tech spending - 2025 Earnings Surprises Detailed Earnings Play Alerts - | 12/18/2025 |
10 | CEO Moves Will XBIT stock rally after Fed decisions - IPO Watch Detailed Earnings Play Strategies - moha.gov.vn | 12/29/2025 |
| Begin Period Cash Flow | 200 M | |
| Total Cashflows From Investing Activities | -1.3 M |
XBiotech Relative Risk vs. Return Landscape
If you would invest 264.00 in XBiotech on October 2, 2025 and sell it today you would lose (25.00) from holding XBiotech or give up 9.47% of portfolio value over 90 days. XBiotech is currently does not generate positive expected returns and assumes 4.6974% risk (volatility on return distribution) over the 90 days horizon. In different words, 42% of stocks are less volatile than XBiotech, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
XBiotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for XBiotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as XBiotech, and traders can use it to determine the average amount a XBiotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0115
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | XBIT |
Based on monthly moving average XBiotech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of XBiotech by adding XBiotech to a well-diversified portfolio.
XBiotech Fundamentals Growth
XBiotech Stock prices reflect investors' perceptions of the future prospects and financial health of XBiotech, and XBiotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on XBiotech Stock performance.
| Return On Equity | -0.16 | ||||
| Return On Asset | -0.11 | ||||
| Current Valuation | (91.09 M) | ||||
| Shares Outstanding | 30.49 M | ||||
| Price To Earning | 1.21 X | ||||
| Price To Book | 0.43 X | ||||
| Price To Sales | 12.23 X | ||||
| Gross Profit | 3.36 M | ||||
| EBITDA | (36.01 M) | ||||
| Net Income | (38.53 M) | ||||
| Cash And Equivalents | 225.79 M | ||||
| Cash Per Share | 7.42 X | ||||
| Total Debt | 10.25 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 28.99 X | ||||
| Book Value Per Share | 5.48 X | ||||
| Cash Flow From Operations | (30.96 M) | ||||
| Earnings Per Share | (0.95) X | ||||
| Market Capitalization | 71.34 M | ||||
| Total Asset | 199.09 M | ||||
| Retained Earnings | (90.84 M) | ||||
| Working Capital | 159.46 M | ||||
| Current Asset | 93.04 M | ||||
| Current Liabilities | 6.29 M | ||||
About XBiotech Performance
Assessing XBiotech's fundamental ratios provides investors with valuable insights into XBiotech's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the XBiotech is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.19) | (0.20) | |
| Return On Capital Employed | (0.23) | (0.24) | |
| Return On Assets | (0.19) | (0.20) | |
| Return On Equity | (0.21) | (0.22) |
Things to note about XBiotech performance evaluation
Checking the ongoing alerts about XBiotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for XBiotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| XBiotech generated a negative expected return over the last 90 days | |
| XBiotech has high historical volatility and very poor performance | |
| Net Loss for the year was (38.53 M) with profit before overhead, payroll, taxes, and interest of 3.36 M. | |
| XBiotech currently holds about 225.79 M in cash with (30.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.42, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| XBiotech has a poor financial position based on the latest SEC disclosures | |
| Roughly 37.0% of the company outstanding shares are owned by insiders | |
| Latest headline from news.google.com: CEO Moves Will XBIT stock rally after Fed decisions - IPO Watch Detailed Earnings Play Strategies - moha.gov.vn |
- Analyzing XBiotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether XBiotech's stock is overvalued or undervalued compared to its peers.
- Examining XBiotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating XBiotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of XBiotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of XBiotech's stock. These opinions can provide insight into XBiotech's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for XBiotech Stock Analysis
When running XBiotech's price analysis, check to measure XBiotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XBiotech is operating at the current time. Most of XBiotech's value examination focuses on studying past and present price action to predict the probability of XBiotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XBiotech's price. Additionally, you may evaluate how the addition of XBiotech to your portfolios can decrease your overall portfolio volatility.